GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Naturewise Biotech & Medicals Corp (ROCO:4732) » Definitions » Capex-to-Revenue

Naturewise Biotech & Medicals (ROCO:4732) Capex-to-Revenue : 0.00 (As of Jun. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Naturewise Biotech & Medicals Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Naturewise Biotech & Medicals's Capital Expenditure for the six months ended in Jun. 2024 was NT$-0.03 Mil. Its Revenue for the six months ended in Jun. 2024 was NT$130.80 Mil.

Hence, Naturewise Biotech & Medicals's Capex-to-Revenue for the six months ended in Jun. 2024 was 0.00.


Naturewise Biotech & Medicals Capex-to-Revenue Historical Data

The historical data trend for Naturewise Biotech & Medicals's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Naturewise Biotech & Medicals Capex-to-Revenue Chart

Naturewise Biotech & Medicals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 - - - -

Naturewise Biotech & Medicals Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 0.01 -

Competitive Comparison of Naturewise Biotech & Medicals's Capex-to-Revenue

For the Biotechnology subindustry, Naturewise Biotech & Medicals's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Naturewise Biotech & Medicals's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Naturewise Biotech & Medicals's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Naturewise Biotech & Medicals's Capex-to-Revenue falls into.



Naturewise Biotech & Medicals Capex-to-Revenue Calculation

Naturewise Biotech & Medicals's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-0.634) / 160.142
=0.00

Naturewise Biotech & Medicals's Capex-to-Revenue for the quarter that ended in Jun. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-0.025) / 130.795
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Naturewise Biotech & Medicals  (ROCO:4732) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Naturewise Biotech & Medicals Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Naturewise Biotech & Medicals's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Naturewise Biotech & Medicals Business Description

Traded in Other Exchanges
N/A
Address
No. 36, Bade Road, 6th Floor, Section 3, Songshan District, Taipei, TWN, 105
Naturewise Biotech & Medicals Corp is a Taiwan-based drug development company that focuses on botanical drug and small molecule therapies. Its products include NBM-BMX Oral Softgel Capsule, Lipocol Forte Capsule, and PPLs Taiwan Green Propolis.

Naturewise Biotech & Medicals Headlines

No Headlines